Nan Fung Group Holdings Ltd Purchases Shares of 28,300 Celcuity, Inc. $CELC

Nan Fung Group Holdings Ltd purchased a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) in the second quarter, according to its most recent 13F filing with the SEC. The fund purchased 28,300 shares of the company’s stock, valued at approximately $2,960,746,000. Celcuity makes up 2.3% of Nan Fung Group Holdings Ltd’s investment portfolio, making the stock its 13th largest position. Nan Fung Group Holdings Ltd owned approximately 0.06% of Celcuity at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Creative Planning bought a new stake in Celcuity during the second quarter valued at $177,000. Rhumbline Advisers increased its stake in Celcuity by 1.2% in the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after acquiring an additional 503 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Celcuity in the 2nd quarter valued at about $169,000. Quantinno Capital Management LP raised its holdings in shares of Celcuity by 20.7% in the 2nd quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock valued at $3,245,000 after acquiring an additional 41,756 shares in the last quarter. Finally, Paloma Partners Management Co boosted its position in shares of Celcuity by 285.8% during the 2nd quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock valued at $1,097,000 after acquiring an additional 60,849 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Trading Down 2.9%

Shares of CELC stock opened at $90.79 on Tuesday. The company has a quick ratio of 8.93, a current ratio of 8.93 and a debt-to-equity ratio of 6.04. The business has a 50-day moving average price of $94.28 and a two-hundred day moving average price of $107.55. Celcuity, Inc. has a 12-month low of $44.42 and a 12-month high of $151.02. The firm has a market cap of $4.44 billion, a P/E ratio of -21.11 and a beta of 0.21.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). Equities analysts anticipate that Celcuity, Inc. will post -4.51 EPS for the current fiscal year.

Analysts Set New Price Targets

CELC has been the subject of several recent analyst reports. Wells Fargo & Company cut their price objective on Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. Guggenheim raised their target price on shares of Celcuity from $165.00 to $175.00 and gave the company a “buy” rating in a research note on Monday, August 17th. Leerink Partners set a $155.00 target price on shares of Celcuity in a research report on Tuesday, June 2nd. Macquarie Infrastructure set a $160.00 price target on shares of Celcuity in a research note on Thursday, May 28th. Finally, Weiss Ratings raised shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $154.55.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.